论文部分内容阅读
目的:探讨利用献血者捐献血液中的白细胞制备的异体细胞因子诱导的杀伤(CIK)细胞与肿瘤靶细胞体外杀伤试验情况。方法:重悬献血者CIK细胞与肝癌细胞、人乳腺癌细胞、白血病细胞、B淋巴瘤细胞浓度,以CIK细胞为效应细胞,肿瘤细胞为靶细胞,使效靶比为32∶1、16∶1、8∶1、4∶1、2∶1、1∶1时共培养48h后检测450nm下的吸收度A值。结果:献血者异体CIK细胞对肝癌、乳腺癌、白血病、B淋巴瘤细胞4种肿瘤靶细胞的杀伤率随着效应细胞数的增加而增大,当效靶比为32∶1时,献血者异体CIK细胞的杀伤率分别为86.1%、84.3%、62.5%、87.9%;献血者异体CIK细胞对肝癌、乳腺癌、B淋巴瘤细胞杀伤活性明显强于白血病细胞,同一效靶比时,CIK细胞对肝癌细胞杀伤活性较高,对白血病细胞杀伤活性较差。结论:献血者CIK细胞对肝癌、人乳腺癌、白血病、B淋巴瘤细胞等肿瘤细胞的生长均有明显的抑制作用。4种肿瘤靶细胞的杀伤率随着效应细胞数的增加而增大,同一效靶比时,CIK细胞对肝癌细胞杀伤活性较高,对白血病细胞杀伤活性较差。
Objective: To investigate the in vitro cytotoxicity (CIK) -cell killing of cytokine-induced killer (CIK) cells and tumor target cells prepared by donating blood leukocytes from blood donors. Methods: The concentrations of CIK cells, hepatocellular carcinoma cells, human breast cancer cells, leukemia cells and B lymphoma cells resuspended in blood donors were measured. CIK cells were used as effector cells and tumor cells were target cells. The effective target ratio was 32: 1, 16: The absorbance A value at 450 nm was measured after 48 h co-culture at 1,8: 1, 4: 1, 2: 1, 1: 1. Results: The killing rate of allogeneic CIK cells on four kinds of tumor target cells of hepatocellular carcinoma, breast cancer, leukemia and B lymphoma cells increased with the number of effector cells. When the target ratio was 32:1, The cytotoxicity of allogeneic CIK cells were 86.1%, 84.3%, 62.5% and 87.9%, respectively. The cytotoxic activity of CIK cells from allogeneic donors to hepatocellular carcinoma, breast cancer and B lymphoma cells was significantly stronger than that of leukemia cells. Cells on the liver cancer cell killing activity is higher, killing activity of leukemia cells is poor. Conclusion: CIK cells from blood donors have obvious inhibitory effects on the growth of liver cancer, human breast cancer, leukemia and B lymphoma cells. The killing rate of the four kinds of tumor target cells increased with the increase of effector cells. When compared with the same effect target, CIK cells had higher cytotoxic activity on liver cancer cells and less cytotoxic activity on leukemia cells.